Across TCGA pan-cancer cohorts, KLHL17 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated KLHL17 data layer compared with 19 for mass-spec protein.
The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher KLHL17 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KLHL17 expression acts as an unfavorable survival marker.
KIRC, LUSC, and KIRP are the cancer types where KLHL17 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.